Miglustat

Miglustat
Clinical data
Trade names	Zavesca, Brazaves, Opfolda
Other names	OGT 918, 1,5-(butylimino)-1,5-dideoxy-D-glucitol, N-butyl-deoxynojirimycin
AHFS/Drugs.com	Monograph
MedlinePlus	a604015
License data	EU EMA: by INN; US DailyMed: Miglustat; US FDA: Miglustat;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	A16AX06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	97%
Protein binding	Nil
Metabolism	Nil
Elimination half-life	6–7 hours
Excretion	Kidney, unchanged
Identifiers
	IUPAC name (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol;
CAS Number	72599-27-0 ;
PubChem CID	51634;
IUPHAR/BPS	4841;
DrugBank	DB00419 ;
ChemSpider	46764 ;
UNII	ADN3S497AZ;
KEGG	D05032;
ChEBI	CHEBI:50381 ;
ChEMBL	ChEMBL1029 ;
CompTox Dashboard (EPA)	DTXSID6045618 ;
ECHA InfoCard	100.216.074
Chemical and physical data
Formula	C10H21NO4
Molar mass	219.281 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O;
	InChI InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 ; Key:UQRORFVVSGFNRO-UTINFBMNSA-N ;
	(verify)

Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease.

It was approved for medical use in the European Union in November 2002, and for medical use in the United States in July 2003.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.